JohnDHainsworthMD

Oncology • Nashville, TN

Co-Founder; Principal Investigator, Sarah Cannon Research Institute

Join to view full profile

Are you Dr. Hainsworth?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 89 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
250 25th Ave N
Ste 100
Nashville, TN 37203
Phone+1 615-320-5090

Fax+1 615-320-1225
Is this information wrong?

Summary

Dr. John Hainsworth, MD is an oncologist in Nashville, Tennessee. He is currently licensed to practice medicine in Tennessee. He is affiliated with TriStar Centennial Medical Center and is a Co-Founder; Principal Investigator at Sarah Cannon Research Institute.

Education & Training

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1981
Vanderbilt University Medical CenterResidency, Internal Medicine, 1976 - 1979
Vanderbilt University School of MedicineClass of 1976

Certifications & Licensure

TN State Medical License 1977 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer Start of enrollment: 2001 Sep 01
Terminated
Phase 2
Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer Start of enrollment: 2001 Apr 01
Completed
Phase 2
Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer Start of enrollment: 1999 Oct 01
Completed
Phase 2
OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2003 Feb 01
Completed
Phase 2
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma Start of enrollment: 2000 Aug 01
Completed
Phase 2
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer Start of enrollment: 2004 May 01
Completed
Phase 2
Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma Start of enrollment: 2004 Jun 01
Completed
Phase 1, Phase 2
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 2
Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients Start of enrollment: 2001 Aug 01
Completed
Phase 2
Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer Start of enrollment: 2003 Mar 01
Completed
Phase 2
Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer Start of enrollment: 2003 Aug 01
Completed
Phase 2
Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma Start of enrollment: 2002 Apr 01
Completed
Phase 2
Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2002 Jan 01
Completed
Phase 2
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2003 Apr 01
Completed
Phase 2
A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma Start of enrollment: 2005 Sep 01
Completed
Phase 2
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma Start of enrollment: 2003 Oct 01
Completed
Phase 2
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Start of enrollment: 2004 Apr 01
Completed
Phase 2
Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma Start of enrollment: 1998 Dec 01
Completed
Phase 2
Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma Start of enrollment: 2002 Mar 01
Completed
Phase 2
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma Start of enrollment: 2004 May 01
Completed
Phase 2
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site Start of enrollment: 2003 Sep 01
Completed
Phase 3
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site Start of enrollment: 2004 Sep 01
Completed
Phase 2
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site Start of enrollment: 2004 Apr 01
Completed
Phase 2
Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma Start of enrollment: 2006 May 01
Completed
Phase 2
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site Start of enrollment: 2006 Jul 01
Completed
Phase 2
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer Start of enrollment: 2006 Oct 01
Completed
Phase 2
Treatment of Head & Neck Cancer With Chemotherapy and Radiation Start of enrollment: 2006 Dec 01
Completed
Phase 2
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer Start of enrollment: 2006 Dec 01
Completed
Phase 1, Phase 2
Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer Start of enrollment: 2007 Feb 01
Completed
Phase 2
High-dose Bevacizumab in Advanced Renal Carcinoma Patients Start of enrollment: 2007 Feb 01
Completed
Phase 2
Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme Start of enrollment: 2007 Apr 01
Completed
Phase 2
Vinflunine in Hormone Refractory Prostate Cancer (HRPC) Start of enrollment: 2007 May 01
Completed
Phase 2
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma Start of enrollment: 2008 Jan 01
Completed
Phase 2
RAD001 Plus Bevacizumab in Metastatic Melanoma Start of enrollment: 2008 Jan 01
Completed
Phase 2
Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2008 Sep 01
Completed
Phase 2
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site Start of enrollment: 2008 Aug 01
Completed
Phase 2
RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM Start of enrollment: 2009 Jan 01
Completed
Phase 2
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary Start of enrollment: 2009 Feb 01
Completed
Phase 2
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma Start of enrollment: 2010 Jan 01
Terminated
Phase 2
Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma Start of enrollment: 2010 Feb 01
Completed
Phase 2
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer Start of enrollment: 2011 Jan 01
Completed
Not Applicable
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma Start of enrollment: 2013 Feb 01
Terminated
Phase 2
Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel Start of enrollment: 2014 Apr 01
Withdrawn
Phase 2
Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer Start of enrollment: 2014 Oct 01
Completed
Phase 1
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma Start of enrollment: 2017 Jan 12
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

4 citations
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
Toni K Choueiri, Camillo Porta, Cristina Suárez, John Hainsworth, Eric Voog, Ignacio Duran, James Reeves, Piotr Czaykowski, Daniel Castellano, Jingjing Chen, Farhad Se...> ;The Oncologist. 2022 Dec 9
30 citations
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study.
Claire F Friedman, John D Hainsworth, Razelle Kurzrock, David R Spigel, Howard A Burris, Christopher J Sweeney, Funda Meric-Bernstam, Yong Wang, Jonathan Levy, Jessica...> ;Cancer Discovery. 2022 Mar 1
5 citations
A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).
Denise A. Yardley, Robyn R. Young, Kerin B. Adelson, Andrea Silber, Jose E. Najera, Davey B. Daniel, N. W. Peacock, L Finney, Susan J. Hoekstra, Mythili Shastry, John ...> ;Clinical Breast Cancer. 2021 Oct 28
4 citations
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial
Susan Halabi, Qian Yang, Andrea Carmack, Shiqi Zhang, Wen-Chi Foo, Tim Eisen, Walter M. Stadler, Robert Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Rober...> ;Kidney Cancer Journal. 2021 Sep 30
137 citations
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
Milind Javle, Mitesh J. Borad, Nilofer S. Azad, Razelle Kurzrock, Ghassan K. Abou-Alfa, Ben George, John D. Hainsworth, Funda Meric-Bernstam, Charles Swanton, Christop...> ;The Lancet. Oncology. 2021 Sep 1
3 citations
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.
Andrew J. Armstrong, Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Robert ...> ;Clinical Cancer Research. 2021 Jun 15
18 citations
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carc...
Thomas Powles, Michael B. Atkins, Bernard Escudier, Robert J. Motzer, Brian I. Rini, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, Mario Sznol, John D. Hainsworth,...> ;European Urology. 2021 May 1
10 citations
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Andrew J. Armstrong, Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Robert ...> ;Clinical Cancer Research. 2021 Jun 15
28 citations
Cancer of Unknown Primary in the Molecular Era.
Shumei Kato, Ahmed Alsafar, Vighnesh Walavalkar, John D. Hainsworth, Razelle Kurzrock> ;Trends in Cancer. 2021 May 1
70 citations
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
Razelle Kurzrock, Daniel W. Bowles, Hyunseok Kang, Funda Meric-Bernstam, John D. Hainsworth, David R. Spigel, Ron Bose, H. A. Burris, Christopher Sweeney, Michael S. B...> ;Annals of Oncology. 2020 Mar 1
5 citations
Phase II trial of eribulin in patients who do not achieve pathologic complete response (pCR) following neoadjuvant chemotherapy
Denise A. Yardley, N. W. Peacock, Brooke R. Daniel, Betrand Anz, David C. Molthrop, Sonalee K. Shroff, Robyn R. Young, Aleksander Jankov, Amy Vander Woude, Mythili Sha...> ;Breast Cancer Research and Treatment. 2020 Feb 14
5 citations
A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
Denise A. Yardley, William Liggett, Mark Mainwaring, Aurelio Castrellon, Laura Blakely, Brian Hemphill, Bertrand Anz, Robyn R. Young, Mythili Shastry, Laura M. DeBusk,...> ;Clinical Breast Cancer. 2020 Apr 1
48 citations
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): ove...
Daniel P. Petrylak, Ronald de Wit, Kim N. Chi, Alexandra Drakaki, Cora N. Sternberg, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aude Flechon, Aristotelis ...> ;The Lancet. Oncology. 2020 Jan 1
23 citations
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squam...
David R. Spigel, Dianna Shipley, David M. Waterhouse, Suzanne F. Jones, Patrick J. Ward, Kent C. Shih, Brian Hemphill, Michael McCleod, Robert C. Whorf, Ray D. Page, J...> ;The Oncologist. 2019 Dec 1
26 citations
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
John D. Hainsworth, Kevin P. Becker, Tarek Mekhail, Sajeel A. Chowdhary, Janice Faulkner Eakle, David Wright, Robert M. Langdon, Kathleen Yost, Gilbert Darin Anthony P...> ;Journal of Neuro-Oncology. 2019 Aug 7
282 citations
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket st...
, , , , , , , , , , , , , , , , > ;The Lancet. Oncology. 2019 Apr 1
6 citations
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer
Denise A. Yardley, Dianna Shipley, John D. Zubkus, Gail Lynn Shaw Wright, Patrick J. Ward, Aruna Mani, Mythili Shastry, L Finney, Laura M. DeBusk, John D. Hainsworth> ;Clinical Breast Cancer. 2019 Feb 1
21 citations
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell ca...
David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Re...> ;Nature Medicine. 2018 Dec 1
8 citations
Cabazitaxel Plus Lapatinib as Therapy for HER2 + Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study
Denise A. Yardley, Lowell L. Hart, Patrick J. Ward, Gail Lynn Shaw Wright, Mythili Shastry, L Finney, Laura M. DeBusk, John D. Hainsworth> ;Clinical Breast Cancer. 2018 Oct 1
24 citations
Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine.
John D. Hainsworth, F. Anthony Greco> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2018 May 23
783 citations
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Re...> ;Nature Medicine. 2018 Jun 1
Reply to J.J. Tao et al
John D. Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R. Spigel, Christopher Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein,...> ;Journal of Clinical Oncology. 2018 Jun 1
11 citations
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non–small cell lung cancer: A randomized, placebo-controlled phase 2 trial with...
David R. Spigel, Howard A. Burris, F. Anthony Greco, Kent C. Shih, Victor G. Gian, Andrew Lipman, Davey B. Daniel, David M. Waterhouse, L Finney, John V. Heymach, John...> ;Cancer. 2018 Jun 1
16 citations
Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset.
F. Anthony Greco, John D. Hainsworth> ;Clinical Genitourinary Cancer. 2018 Aug 1
8 citations
Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).
John D. Hainsworth, David M. Waterhouse, Kent C. Shih, Ralph V. Boccia, Victor M. Priego, Michael McCleod, Fred J. Kudrik, Reed Brian Mitchell, Howard A. Burris, F. An...> ;Lung Cancer. 2018 Apr 1
Join now to see all

Press Mentions

Precision Medicine to Expand Cancer TherapiesJuly 10th, 2016
Liquid Biopsy May Aid Treatment Decisions in Solid TumorsJuly 5th, 2016
Targeting Molecular Abnormalities with off-Label IndicationsJune 7th, 2016
Join now to see all

Hospital Affiliations

TriStar Centennial Medical CenterNashville, Tennessee